Dr Krystyn Van Vliet on Tackling Scalability, Cost When Using 3D Platforms for MS Drug Discovery

Krystyn Van Vliet, PhD, of Cornell University, discusses the scalability of 3D platforms in multiple sclerosis (MS) drug discovery and compares their costs with those of other drug discovery methods.

Related Keywords

Anna Jagielska ,Daniela Espinosa Hoyos ,Krystyn Van Vliet ,Cornell University Meinig School Of Biomedical Engineering ,Americas Committee For Treatment ,Cornell University ,Meinig School ,Biomedical Engineering ,Americas Committee ,Overcome Barriers ,Drug Discovery ,Artificial Axon ,Artificial Axon Labs ,